Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT07177612
Enrolling by invitation Observational

Implementation Research on the LILAC Method to Educate Management of Elevated Lipoprotein(a).

NCT07177612 · tracked via the Priya Life Science Australia tracker
Sponsor
Changi General Hospital
Phase
Observational
Started
2025-09-09
Last updated
2025-09-22

Condition(s) studied

Lipoprotein(a)Lipoprotein(a), Hyper-Lp(a)-Emia

Study summary

The goal of this observational study is to assess the if short educational videos about #LILAC-for-Lpa are feasible and accepted in improving the confidence, testing, and management on Lipoprotein(a).

Eligibility

Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants include students, participants from institute of higher learning aged 16 and above. * Participants aged 16 and above regardless of local or overseas, may also be from educational talks that Dr Loh is invited to speak at. * Patients and members of the public aged 16 and above if they attend lipid awareness educational events. * Participants aged 16 and above in patient support groups or patient advocacy networks. Exclusion Criteria: * Participants aged below 16 years old.

Primary outcome measure(s)

  • Improvement of Knowledge and awareness of Lp(a) — From enrolment to 3 months after
    Survey and questionnaire on participants to assess knowledge and awareness

Trial sites (3)

FacilityCityRegionStatus
Online Portal, Australia Perth Australia
Online web portal Kuala Lumpur Malaysia
Changi General Hospital Singapore Singapore

Other trials for the same condition

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07177612 on ClinicalTrials.gov ↗ ← All trials in Australia